@Tom, bioequivalence is a nice concept, but proving it generally entails proving a negative (no significant difference) and proving a negative is generally difficult. Rare side-effects are rare and therefore will not show up (or be measured) in a study. In addition, even for the outcomes that are measured, the regulator allows some degree of difference.
It is also, in the case mentioned here, needless; and there's an old saying about not messing about with things that work.
Finally, I would ask you to avoid ad hominem arguments and personal attacks on my blog.
⇧
The Coversyl switch
